Journal of Current Glaucoma Practice

Register      Login

VOLUME 17 , ISSUE 2 ( April-June, 2023 ) > List of Articles


Efficacy and Safety Outcomes of XEN Implantation and Gonioscopy-assisted Transluminal Trabeculotomy for the Management of Advanced Open-angle Glaucoma

Sunil Ruparelia, Mohammed Sharif, Nir Shoham-Hazon

Keywords : Glaucoma, Gonioscopy-assisted transluminal trabeculotomy, Minimally invasive glaucoma surgery, Open-angle glaucoma, XEN

Citation Information : Ruparelia S, Sharif M, Shoham-Hazon N. Efficacy and Safety Outcomes of XEN Implantation and Gonioscopy-assisted Transluminal Trabeculotomy for the Management of Advanced Open-angle Glaucoma. J Curr Glaucoma Pract 2023; 17 (2):63-67.

DOI: 10.5005/jp-journals-10078-1394

License: CC BY-NC 4.0

Published Online: 11-07-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Aim: Minimally invasive glaucoma surgery (MIGS) is not typically used in patients with advanced-stage glaucoma. This study describes the outcomes and complications of patients with advanced open-angle glaucoma (OAG) who underwent XEN implantation with cataract surgery or gonioscopy-assisted transluminal trabeculotomy (GATT) with cataract surgery. Methods: This retrospective study identified patients who had undergone XEN implantation or GATT for the management of advanced OAG. Outcomes included surgical success, intraocular pressure (IOP) reduction, number of topical IOP-lowering drops, visual field mean deviation (MD), best-corrected visual acuity (BCVA), and complications. Surgical success was defined as an IOP of <14 mm Hg and a 20% reduction at 12 months without topical IOP-lowering drops (complete success) or with topical IOP-lowering drops (qualified success). Results: Exactly 70 eyes were enrolled in this study, including 35 who had undergone XEN implantation and 35 who had undergone GATT. The overall surgical success rate was 74.3% (26 of 35) for eyes that underwent XEN implantation and 71.4% (25 of 35) for eyes that underwent GATT. Percent IOP reduction from baseline to 12 months postoperatively was 48% in the XEN cohort and 32% in the GATT cohort. Significant reduction in the use of topical IOP-lowering drops was demonstrated for both XEN (3.26 ± 1.15–1.23 ± 1.28) (p < 0.001) and GATT (2.46 ± 1.12–0.43 ± 0.78) (p < 0.001) cohorts at 12 months postoperatively. The only complication reported was transient hyphema, which occurred in three patients from the XEN group and four from the GATT group, and resolved spontaneously. Conclusions: Both XEN implantation and GATT may be safe and effective management options when treating patients with advanced OAG. However, larger sample sizes are required to make direct statistical comparisons between these techniques. Clinical significance: In this study, XEN implantation and GATT combined with cataract surgery were each associated with favorable outcomes in patients with advanced OAG.

  1. Zhang N, Wang J, Li Y, et al. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep 2021; 11(1):13762. DOI: 10.1038/s41598-021-92971-w
  2. Resnikoff S, Pascolini D, Mariotti SP, et al. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ 2008;86(1):63–70. DOI: 10.2471/blt.07.041210
  3. Post M, Lubiński W, Śliwiak D, et al. XEN Gel stent in the management of primary open-angle glaucoma. Doc Ophthalmol 2020;141(1):65–76. DOI: 10.1007/s10633-020-09753-4
  4. Rafuse PE. The optimal trabeculectomy: patient and procedure. Can J Ophthalmol 2014;49(6):523–527. DOI: 10.1016/j.jcjo.2014.08.008
  5. Shah M. Micro-invasive glaucoma surgery - an interventional glaucoma revolution. Eye Vis (Lond) 2019;6:29. DOI: 10.1186/s40662-019-0154-1
  6. Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: where is the evidence? Asia Pac J Ophthalmol (Phila) 2020;9(3):203–214. DOI: 10.1097/APO.0000000000000294
  7. Fea AM, Durr GM, Marolo P, et al. XEN® gel stent: a comprehensive review on its use as a treatment option for refractory glaucoma. Clin Ophthalmol 2020;14:1805–1832. DOI: 10.2147/OPTH.S178348
  8. Vera V, Sheybani A, Lindfield D, et al. Recommendations for the management of elevated intraocular pressure due to bleb fibrosis after XEN gel stent implantation. Clin Ophthalmol 2019;13:685–694. DOI: 10.2147/OPTH.S195457
  9. Bozkurt E, Yenihayat F, Olgun A, et al. The efficacy of gonioscopy-assisted transluminal trabeculectomy combined with phacoemulsification. Int Ophthalmol 2021;41(1):35–43. DOI: 10.1007/s10792-020-01550-x
  10. Aktas Z, Ucgul AY, Bektas C, et al. Surgical outcomes of prolene gonioscopy-assisted transluminal trabeculotomy in patients with moderate to advanced open-angle glaucoma. J Glaucoma 2019;28(10):884–888. DOI: 10.1097/IJG.0000000000001331
  11. Laborda-Guirao T, Cubero-Parra JM, Hidalgo-Torres A. Efficacy and safety of XEN 45 gel stent alone or in combination with phacoemulsification in advanced open angle glaucoma patients: 1-year retrospective study. Int J Ophthalmol 2020;13(8):1250–1256. DOI: 10.18240/ijo.2020.08.11
  12. Kalina AG, Kalina PH, Brown MM. XEN® gel stent in medically refractory open-angle glaucoma: results and observations after one year of use in the United States. Ophthalmol Ther 2019;8(3):435–446. DOI: 10.1007/s40123-019-0192-8
  13. Olgun A, Aktas Z, Ucgul AY. XEN gel implant versus gonioscopy-assisted transluminal trabeculotomy for the treatment of open-angle glaucoma. Int Ophthalmol 2020;40(5):1085–1093. DOI: 10.1007/s10792-019-01271-w
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.